Analysis of Segments and Major Growth Areas in the Open-Angle Glaucoma (OAG) Market

The open-angle glaucoma (OAG) market is positioned for substantial expansion in the coming years, driven by advances in treatment accessibility and evolving therapeutic approaches. With growing awareness and improved technologies, this sector is set to experience notable growth and innovation through 2030.

Projected Market Valuation and Growth Trajectory of the Open-Angle Glaucoma Market
The open-angle glaucoma market is anticipated to reach a valuation of $8.86 billion by 2030, registering a compound annual growth rate (CAGR) of 6.2%. Key factors propelling this growth include the increased demand for accessible online therapy options and a rising adoption of mobile and web-based counseling tools. Additionally, the integration of artificial intelligence-powered mental wellness solutions and the expanding use of hybrid therapy models that combine individual and group sessions are significant contributors. The broadening availability of online therapy in both commercial and residential sectors further supports this market's upward trajectory. Important trends expected to influence the market during the forecast period include greater use of prostaglandin analog drugs, the rise of minimally invasive glaucoma surgeries, heightened awareness of early diagnosis and screening, increased teleophthalmology consultations for OAG management, and the development of combination drug therapies.

Download a free report of the open-angle glaucoma (oag) market report:
https://www.thebusinessresearchcompany.com/report/open-angle-glaucoma-oag-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Players Leading the Open-Angle Glaucoma Market
Several prominent companies currently dominate the open-angle glaucoma market. These include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Alcon Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Santen Pharmaceuticals, Théa Pharma, Glaukos Corporation, Quantel Medical, EyePoint Pharmaceuticals Inc., iSTAR Medical, Nicox Ophthalmics, Visus Therapeutics, Inotek Pharmaceuticals, Hoya Corporation, Boston Scientific, Ocular Therapeutix Inc., Carl Zeiss Meditec AG, Topcon Corporation, Nidek Co. Ltd., Heidelberg Engineering GmbH, and New World Medical Inc.

Strategic Acquisition Enhancing Alcon's Glaucoma Portfolio
In July 2024, Alcon Inc., a Swiss ophthalmology firm, completed the acquisition of BELKIN Vision Ltd. for $81 million. This strategic move aims to strengthen Alcon's glaucoma treatment lineup by adding the direct selective laser trabeculoplasty (DSLT) device-a pioneering first-line laser therapy for open-angle glaucoma. This acquisition aligns with Alcon's global mission to expand access to innovative and minimally invasive treatment options. BELKIN Vision Ltd., headquartered in Israel, specializes in medical devices focused on open-angle glaucoma management.

View the full open-angle glaucoma (oag) market report:
https://www.thebusinessresearchcompany.com/report/open-angle-glaucoma-oag-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Innovations and Trends in the Open-Angle Glaucoma Market
Companies within the open-angle glaucoma market are increasingly focusing on developing advanced therapeutic solutions, such as rehabilitation robots that provide personalized treatments and accelerate recovery for patients with neurological or musculoskeletal impairments. Rehabilitation robots are automated devices designed to assist patients in regaining motor functions in the upper or lower limbs through guided exercises, repetitive movements, and therapy customization.

For example, in November 2023, Shanghai Siyi Intelligent Technology Co. Ltd., a China-based tech company, introduced two new products: the upper limb rehabilitation robot (SY-UEA2) and the hand rehabilitation robot (BCI) SY-BR09. The SY-UEA2 supports arm and shoulder recovery with precise optical positioning, adaptive training modes, and real-time motion feedback, enabling comprehensive rehabilitation both at home and in clinics. Meanwhile, the SY-BR09 employs brain-computer interface technology alongside flexible robotics to restore fine motor control, promoting neural rewiring and faster recovery for patients suffering from stroke or nerve injuries. These devices offer intelligent, interactive, and tailored neurorehabilitation solutions to improve patient independence, mobility, and quality of life.

Detailed Segmentation of the Open-Angle Glaucoma Market
This report categorizes the open-angle glaucoma market into several key segments:
1) Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, and Other Disease Types
2) Drug Class: Prostaglandin Analog, Beta Blockers, Adrenergic Agonist, Carbonic Anhydrase Inhibitors, and Other Drug Classes
3) End User: Hospitals, Homecare, Specialty Clinics, and Other End Users
4) Distribution Channel: Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy

Subcategories include:
- Open Angle Glaucoma: Primary Open-Angle Glaucoma (POAG) and Secondary Open-Angle Glaucoma
- Angle Closure Glaucoma: Acute Angle-Closure Glaucoma and Chronic Angle-Closure Glaucoma
- Other Disease Types: Normal-Tension Glaucoma, Congenital Glaucoma, and Secondary Glaucoma

This structured segmentation allows for a comprehensive understanding of market dynamics across various treatment types, patient settings, and distribution avenues.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.